BIND Therapeutics: JMP Securities Healthcare Conference (BIND Therapeutics) - Jul 11, 2014 - "BIND-014 Phase 1: Well Tolerated and Promising Signs of Clinical Activity"; "Once Every Week Schedule in Phase 1 Trial (N =27)"; "Well tolerated with predictable and manageable toxicity"; "No new or unexpected toxicities observed"; "Maximum Tolerated Dose declared at 40 mg/m2, dose-limiting toxicities were neutropenia and mucositis"; "Traditional docetaxel toxicities observed generally at low frequency and grade"; "Clinical activity: 2 PR (Breast, GI): 5 SD > 12 weeks (NSCLC, neuroendocrine, GI)"; "Weekly dosing schedule provides 50% greater drug exposure than 3 Weekly schedule"
P1 data • Breast Cancer • Non Small Cell Lung Cancer • Oncology
|